Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer from parp Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Susana Banerjee comments on data, during a press conference at the 2019 ESMO congress, from the PAOLA-1/ENGOT-ov25 trial.nnThis was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)